Syros Pharmaceuticals Inc (SYRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Sales | 5,467 | 7,802 | 5,697 | 5,162 | 4,827 |
| Gross Profit | 5,467 | 7,802 | 5,697 | 5,162 | 4,827 |
| Operating Expenses | 32,120 | 33,226 | 32,608 | 31,306 | 25,768 |
| Operating Income | -26,653 | -25,424 | -26,911 | -26,144 | -20,941 |
| Interest Expense | 976 | 987 | 984 | 969 | 967 |
| Other Income | 2,483 | 2,598 | 1,868 | 4,623 | 7,680 |
| Pre-tax Income | -25,146 | -23,813 | -26,027 | -22,490 | -14,228 |
| Net Income Continuous | -25,146 | -23,813 | -26,027 | -22,490 | -14,228 |
| Net Income | $-25,146 | $-23,813 | $-26,027 | $-22,490 | $-14,228 |
| EPS Basic Total Ops | -3.99 | -3.80 | -4.14 | -3.60 | -2.30 |
| EPS Basic Continuous Ops | -3.99 | -3.81 | -4.14 | -3.58 | -2.32 |
| EPS Diluted Total Ops | -3.99 | -3.80 | -4.14 | -3.60 | -2.30 |
| EPS Diluted Continuous Ops | -3.99 | -3.81 | -4.14 | -3.58 | -2.32 |
| EBITDA(a) | $-25,787 | $-24,466 | $-25,966 | $-25,221 | $-20,043 |